---
figid: PMC8876564__pharmaceuticals-15-00172-g002
figtitle: Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left
  Ventricular Myocardial Function in Psoriasis
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8876564
filename: pharmaceuticals-15-00172-g002.jpg
figlink: /pmc/articles/PMC8876564/figure/pharmaceuticals-15-00172-f002/
number: F2
caption: Schematic representation of the molecular mechanism of action of apremilast
  and the possible effects on cardiovascular system. The inhibition of phosphodiesterase
  4 (PDE4) by apremilast increases intracellular levels of cAMP leading to activation
  of protein kinase A (PKA). This enzyme induces cAMP responsive element binding protein
  (CREB) phosphorylation which subsequently induces release of anti-inflammatory cytokines.
  Moreover, PKA inhibits the nuclear factor kappa B (NF-κB) pathway, resulting in
  the suppression of major pro-inflammatory cytokines. Apremilast improves oxidized
  low-density lipoprotein (LDL)-induced endothelial dysfunction via the rescue of
  Krüppel like factor-6 expression and presents beneficial metabolic effects, suggesting
  a potential role for apremilast in the improvement of cardiovascular function.
papertitle: Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left
  Ventricular Myocardial Function in Psoriasis.
reftext: Ignatios Ikonomidis, et al. Pharmaceuticals (Basel). 2022 Feb;15(2):172.
year: '2022'
doi: 10.3390/ph15020172
journal_title: Pharmaceuticals
journal_nlm_ta: Pharmaceuticals (Basel)
publisher_name: MDPI
keywords: psoriasis | phosphodiesterase 4 | apremilast | endothelial glycocalyx |
  perfused boundary region | myocardial deformation
automl_pathway: 0.7880729
figid_alias: PMC8876564__F2
figtype: Figure
redirect_from: /figures/PMC8876564__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8876564__pharmaceuticals-15-00172-g002.html
  '@type': Dataset
  description: Schematic representation of the molecular mechanism of action of apremilast
    and the possible effects on cardiovascular system. The inhibition of phosphodiesterase
    4 (PDE4) by apremilast increases intracellular levels of cAMP leading to activation
    of protein kinase A (PKA). This enzyme induces cAMP responsive element binding
    protein (CREB) phosphorylation which subsequently induces release of anti-inflammatory
    cytokines. Moreover, PKA inhibits the nuclear factor kappa B (NF-κB) pathway,
    resulting in the suppression of major pro-inflammatory cytokines. Apremilast improves
    oxidized low-density lipoprotein (LDL)-induced endothelial dysfunction via the
    rescue of Krüppel like factor-6 expression and presents beneficial metabolic effects,
    suggesting a potential role for apremilast in the improvement of cardiovascular
    function.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CrebB
  - CrebA
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - dnc
  - Dif
  - dl
  - Rel
  - Amph
  - modSP
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - PDE4A
  - PDE4B
  - PDE4C
  - PDE4D
  - NFKB1
  - APRT
  - MFAP1
---
